Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech is an immuno-pharma company focused on developing therapeutics for cancers with unmet needs, viral diseases, and immune-deficiency disorders. Their flagship products, Ampligen and Alferon N Injection, have billion-dollar market potential. Despite reporting a net loss in recent quarters due to being in early and clinical development stages, AIM's decision to focus on Ampligen for the treatment of late-stage pancreatic cancer presents a high potential for success. With multiple ongoing and planned clinical trials and potential positive clinical data, there is a strong likelihood of the stock's success over the upcoming year. Furthermore, AIM's current valuation is attractive for investors looking for potential high growth in the biotech sector. However, risks to attaining the price target include potential failures in product development, regulatory approvals, and competition in the market.

Bears say

AIM ImmunoTech is heavily dependent on the success of their currently ongoing Phase 2 clinical study for Ampligen in combination with AstraZeneca's Imfinzi for pancreatic cancer, which is a high-risk endeavor. Additionally, the company's balance sheet shows a concerning level of debt and their recent stock sales signal a need for cash, indicating potential financial struggles going forward. The company's market potential may be high, but it likely won't be realized for at least another 3 years.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.